The FDA has extended the review period for Bristol Myers Squibb Co's BMY supplemental application for Reblozyl (luspatercept-aamt) for anemia in adults with non-transfusion-dependent (NTD) beta-thalassemia.
- The agency has pushed the decision to June 27 from March 27, granted earlier under priority review.
- The application was based on results from the pivotal Phase 2 BEYOND study evaluating Reblozyl plus best supportive care.
- An application (Type II variation) is also under review by the European Medicines Agency.
- Reblozyl is currently approved to address transfusion-dependent anemia-associated beta-thalassemia and lower-risk myelodysplastic syndromes failing an erythropoietin-stimulating agent (ESA) and requiring red blood cell transfusions.
- Separately, the Japanese regulatory authority has accepted the supplemental application for Breyanzi (lisocabtagene maraleucel) for the second-line treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
- Price Action: BMY shares are closed 0.11% higher at $72.50 during after-hours trading on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in